<div>
  <ul>
    <li>
      <p>
        Lycia Therapeutics has raised ~USD 107 million in a Series C funding round led by Venrock Healthcare Capital Partners. with participation from new investors including Janus Henderson Investors, Marshall Wace, Franklin Templeton, as well as existing investors such as Redmile Group, RTW Investments, and Eli Lilly and Company.
      </p>
    </li>
    <li>
      <p>
        The company expects to use the funds to advance its lead therapeutic candidates, which focus on autoimmune and inflammatory diseases, into the clinical stage.&nbsp;
      </p>
    </li>
    <li>
      <p>
        Lycia Therapeutics is a biotechnology firm specializing in developing novel therapeutics through its proprietary Lysosomal Targeting Chimera (LYTAC) platform. This platform is designed to degrade extracellular and membrane-bound proteins often implicated in autoimmune disorders and cancers. The company's approach targets undruggable proteins, focusing on autoimmune and inflammatory diseases​.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://lyciatx.com/lycia-therapeutics-completes-106-6-million-series-c-financing-to-advance-pipeline-of-lytac-extracellular-protein-degraders-to-the-clinic/">
      Press release
    </a>
  </p>
  <p>
  </p>
</div>


Precision Medicine

<div>
 <p>Lycia Therapeutics, a biotechnology company, has garnered approximately USD 107 million through a Series C funding round. The funding round was steered by Venrock Healthcare Capital Partners and saw the participation of several new investors like Janus Henderson Investors, Marshall Wace, and Franklin Templeton, alongside existing contributors including Redmile Group, RTW Investments, and Eli Lilly and Company.</p>
 <p>The raised capital is expected to be deployed towards advancing Lycia Therapeutics' principal therapeutic candidates connected to autoimmune and inflammatory diseases, into the clinical stage. </p>
 <p>Lycia Therapeutics' main specialization lies in creating cutting-edge therapeutics through its unique platform called Lysosomal Targeting Chimera (LYTAC). This platform's main functionality is to degrade extracellular and membrane-bound proteins that are usually found in autoimmune disorders and cancers. By targeting these so-called 'undruggable' proteins, the company mainly focuses on autoimmune and inflammatory diseases.</p>
 
</div>

Lycia Therapeutics raises USD 107 million in Series C funding for clinical development of lead therapeutic candidates

Using online platforms, autonomy, electric and fuel-cell tech solutions to shape the future of trucking.

Truck Industry Tech

ANALYST_QUICK_TAKE

PROMINENT_CATEGORY

<div>
 <p>Hyzon, a provider of hydrogen fuel-cell technology, has successfully conducted a two-week trial of its Class 8 200 kW fuel-cell electric vehicle (FCEV) truck with IMC Logistics. The vehicle covered over 1,000 miles in the Houston market during this period.</p>
 <p>IMC Logistics gave positive reviews from drivers involved in the trial. This test is part of their research into the use of hydrogen fuel cell technology within their fleet based in Texas.</p>
 <p>This trial is a component of a broader testing initiative by Hyzon. The company has undertaken eight successful trials of its 200 kW Class 8 and refuse truck platforms since July 2024. Hyzon also has 20 large fleet trials in progress for its truck platforms, scheduled to go on until February 2025.</p>
 
</div> <p><b>Analyst QuickTake:<br>
 </b> Hyzon most <a href="https:<br>
//sp-edge.com/updates/35420"> recently </a> completed a Class 8 200 kW FCEV truck trial in partnership with TALKE, a logistics solutions provider for the chemical industry.</p>

Hyzon completes successful trial of hydrogen fuel-cell truck with IMC

Technologies bringing about a new reality

Extended Reality

INCUMBENTS_PRESENT

<div>
 <p>Cisco Webex, a Cisco subsidiary, has upgraded its video conferencing platform to include XR features and better support for Apple Vision Pro. These XR features enable users to convert a normal meeting room with a Cisco Room Bar Pro into a fully immersive virtual studio. The firm plans to utilize this service for purposes like demonstrations, remote training, and educational initiatives.&nbsp;</p>
</div> <p><b>Analyst </b> <b>QuickTake:<br>
 </b> Cisco's past ventures in XR are evident in initiatives such as <a href="https:<br>
//newsroom.cisco.com/c/r/newsroom/en/us/a/y2021/m10/wx1-hologram-release-placeholder.html"> introducing AR </a> into its platforms and providing immersive 3D meeting environments. With the resurgence of XR services in many professional industries, Cisco aims to establish itself as a trusted authority in delivering immersive workplace experiences.</p>

Cisco Webex launches spatial meetings with continued integration of Apple Vision Pro

Promising research and receding stigma are giving investors cannabis-boom flashbacks.

Psychedelic Medicine

<div>
 <p>Enveric Biosciences, a neuroplastogen development biotechnology company, recently announced the addition of five US patents and the allowance of three patent applications to its EVM301 portfolio.</p>
 <p> These latest patents, numbered 11,845,727, 11,858,895, 11,891,359, 11,998,557, and 12,128,058, have increased the total count of issued US patents protecting the EVM301 portfolio and the company's library of drug candidates to nine.</p>
 <p>According to CEO Dr. Joseph Tucker, this expanded patent portfolio includes a broad variety of tryptamine derivative molecules, such as carboxylated, aminated, prenylated, glycosylated, nitrilated, and halogenated derivatives.</p>
</div>

Enveric Biosciences expands EVM301 patent portfolio with new issuances

Pushing the envelope in MedTech with emerging technologies

Next-gen Medical Devices

<div>
 <p>Akura Medical has been given FDA Investigational Device Exemption (IDE) approval to initiate the QUADRA-PE study for testing its Katana Thrombectomy System on patients suffering from acute pulmonary embolism. This large-scale international trial will cover 26 global sites and envisions the enrollment of about 118 patients.</p>
 <p>Incuding features like a bidirectional low-profile sheath, high-speed saline jets for clot degradation, sensors for real-time checking of pulmonary artery pressure, and the Sentinel console to monitor clot engagement and blood loss, the Katana System will be evaluated for efficiency by measuring the reduction in the right ventricular/left ventricular ratio and its safety by keeping track of major adverse events.</p>
 <p>As of now, the system is only intended for investigational use and has not been given clearance for sale in the US or other countries. Columbia University Medical Center and Tristar Centennial Medical Center will jointly lead the trial.</p>
</div>

Akura Medical receives FDA approval for pulmonary embolism trial

<div>
 <p>The medical technology firm Boston Scientific Corporation is set to acquire Cortex, Inc., a company specialising in diagnostic mapping solutions for atrial fibrillation (AF). The acquisition will be for an unknown amount. </p>
 <p>The OptiMap System, a product developed by Cortex, utilises a basket catheter and a unique algorithm to identify potential sources of active AF. The system assists practitioners in creating ablation strategies tailored to individual patients. After gaining FDA 510(k) clearance in 2023, the system showed a 51% increase in AF freedom compared to traditional therapy in clinical trials.</p>
 <p>The acquisition, which is expected to be finalised in the first half of 2025, is set to enhance Boston Scientific's electrophysiology portfolio. This will be achieved through the addition of distinct cardiac mapping technology for intricate AF cases. The acquisition also includes plans for furthering the technology and expanding its global reach.</p>
 
</div>

Boston Scientific to acquire Cortex for undisclosed sum

Membership-based, non-insurance healthcare companies helping maintain a steady state of well being.

Preventive Healthcare

<div>
 <p>Cardiac monitoring systems manufacturer, iRhythm Technologies, has been granted a second FDA 510(k) clearance for design alterations and labeling updates to its Zio AT wearable cardiac monitoring system. This clearance was received only one week after gaining the first 510(k) clearance for design changes.</p>
 <p>iRhythm has intensified its efforts in boosting its quality management system. The company has grown its regulatory and quality-related staff from 20 to over 100, appointed a new leader for quality management, and partnered with a consulting firm to facilitate internal audits. Additionally, the firm has decided to postpone its FDA submission for the upcoming Zio MCT device till the third quarter of 2025, planning for a launch in the following year.</p>
</div> <p><b>Analyst QuickTake:<br>
</b> In May 2023, the FDA <a href="https:<br>
//cardiovascularbusiness.com/topics/healthcare-management/healthcare-policy/fda-warning-letter-irhythm"> issued </a> a warning letter to iRhythm Technologies, highlighting serious compliance issues regarding its Zio AT mobile cardiac telemetry device. The recent clearance addresses design modifications and required labeling updates regarding manufacturing facility issues this warning letter highlights.</p>

iRhythm receives FDA 510(k) clearance for Zio AT cardiac monitor updates

More important now than ever, telehealth will long outlast the pandemic that drove its growth.

Telehealth

<div>
 
 <p>Telehealth company Yazen Health has secured EUR 19.5 million (USD 21.2 million) in Series A funding. The round was co-led by Evli Growth Partners and Helsana HealthInvest, with participation from Almaz Capital, Yabeo, Luminar Ventures, and Aggregate Media. This increase brings Yazen Health's total funding to date to EUR 23.9 million (USD 26.0 million).</p>
 <p>The company intends to use this new funding to expand operations overseas into Spain, Norway, and the Netherlands, as well as to reinforce their presence in the UK and Germany. A portion of the funds will also be allocated towards further development of the Yazen app and their care service platform, which functions to connect healthcare professionals with patients in need.</p>
 <p>Yazen Health, which boasts an annual recurring revenue of EUR 18 million (USD 19.6 million) from its profitable base in Sweden, has 20,000 active patients. They claim a 70% patient retention rate after the first year. The company operates with a team of 150, half of whom are general practitioners. Yazen Health has also reported that they have assisted patients in achieving over 200 tons of total weight loss collectively.</p>
 
</div>

Yazen Health raises EUR 19.5 million in Series A funding to expand internationally

Driving livestock productivity using next-generation biotechnology

Livestock Biotech

<div>
 <p>UK's Tesco has teamed up with dairy suppliers Arla and Muller to initiate the "Future Dairy Partnership". The partnership is dedicated to enhancing the sustainability of the dairy sector.</p>
 <p>Involving all 400 of Tesco's Sustainable Dairy Group farmers, the partnership will primarily work towards slashing on-farm emissions by 30% by 2030. The central initiatives include experimenting with methane-reducing feed additives, implementing eco-friendly farming practices, and creating a sustainable dairy blueprint for farmers.</p>
 <p>This collective effort will also result in an industry-wide report on sustainable dairy methods, provide financial backing for sustainability aims, and will extend an invitation to other organizations in the dairy industry to join this initiative.</p>
 
</div> <p><b>Analyst QuickTake:<br>
 </b> Recently, Cargill invested <a href="https:<br>
//sp-edge.com/updates/35574"> USD 1 million </a> in research to reduce methane emissions from cattle. Furthermore, <a href="https:<br>
//sp-edge.com/updates/33852"> Ajinomoto and Danone </a> partnered to create novel feed additives to curb methane output. These developments underscore a growing commitment among leading players to innovate solutions that align with environmental goals and the evolving expectations for sustainable food production.</p>

Tesco partners with Arla and Muller to transform UK dairy sustainability practices

<div>
 <p>dsm-firmenich, a major healthcare, nutrition, and cosmetic products manufacturer, has received approval from the Japanese Ministry of Agriculture, Forestry and Fisheries for Boavaer, its methane-reducing livestock feed additive. Based on studies, utilising around a quarter teaspoon of Bovaer every day per cow can decrease methane emissions by roughly 30% for dairy cows and 45% for beef cattle.</p>
 <p>This approval is in line with Japan's MIDORI strategy, introduced in May 2021, which is devoted to developing sustainable food systems and lowering agricultural methane emissions. This additionally assists Japan in fulfilling its Global Methane Pledge to decrease methane emissions by 11% relative to 2013 by 2030.</p>
</div> <p><b>Analyst QuickTake:<br>
 </b> In <a href="https:<br>
//sp-edge.com/updates/29808"> May 2024 </a> , Boaver received approval from the FDA after a multi-year comprehensive review, which deemed it in line with safety and efficacy requirements for use in cattle. Besides reducing emissions, Boaver provides farmers with a potential extra revenue source through carbon credit schemes.</p>

dsm-firmenich secures approval for Bovaer in Japan

Autonomous and connected technologies shaping the future of the auto industry

Auto Tech

<div>
 <p>Arbe Robotics, a real-time 4D imaging radar software developer based in Israel, secured funding of $15 million through a public offering. The round saw participation from institutional investors such as AWM Investment Company. The offering included 8,250,000 ordinary shares with Tranche A and B warrants. There is scope for an additional $34.4 million in proceeds if Tranche A and B warrants are fully exercised on a cash basis.</p>
 <p>The company intends to allocate the net proceeds towards working capital and a variety of corporate objectives.</p>
</div>

All Updates

Lycia Therapeutics raises USD 107 million in Series C funding for clinical development of lead therapeutic candidates

Hyzon completes successful trial of hydrogen fuel-cell truck with IMC

Cisco Webex launches spatial meetings with continued integration of Apple Vision Pro

Enveric Biosciences expands EVM301 patent portfolio with new issuances

Akura Medical receives FDA approval for pulmonary embolism trial

Boston Scientific to acquire Cortex for undisclosed sum

iRhythm receives FDA 510(k) clearance for Zio AT cardiac monitor updates

Yazen Health raises EUR 19.5 million in Series A funding to expand internationally

Tesco partners with Arla and Muller to transform UK dairy sustainability practices

dsm-firmenich secures approval for Bovaer in Japan

Arbe Robotics closes up to USD 49 million in public offering

Precision Medicine

Lycia Therapeutics raises USD 107 million in Series C funding for clinical development of lead therapeutic candidates

Contact us